Abstract
Introduction We describe the 24-month incidence of Dolutegravir (DTG)-containing antiretroviral treatment (ART) initiation since its introduction in 2019 in West Africa.
Methods We included all patients aged 0-24 years on ART from nine clinics in Côte d’Ivoire (n=4), Ghana, Nigeria, Mali, Benin, and Burkina Faso. Baseline varied by clinic and was defined as date of first DTG prescription; patients were followed up until database closure/death/loss to follow-up (LTFU, no visit ≥ 7 months), whichever came first. We computed the cumulative incidence function for DTG initiation; associated factors were explored in a shared frailty model, accounting for clinic heterogeneity.
Results Since 2019, 3,350 patients were included; 47.2% were female;78.9% had been on ART ≥ 12 months. Median baseline age was 12.5 years (Interquartile range[IQR]: 8.4-15.8). Median follow-up was 14 months (IQR: 7-22). The overall cumulative incidence of DTG initiation reached 22.7% (95% Confidence Interval (CI): 21.3-24.2) and 56.4% (95% CI: 54.4-58.4) at 12 and 24 months, respectively. In univariate analyses, those aged <5 years and females were overall less likely to switch. Adjusted on ART line and available viral load (VL) at baseline, females >10 years were less likely to initiate DTG compared to males of the same age (adjusted Hazard Ratio [HR] among 10-14 years: 0.62, 95% CI: 0.54-0.72; among ≥15 years: 0.43, 95% CI: 0.36-0.50), as were those with detectable VL (> 50 copies/mL) compared to those in viral suppression (aHR: 0.86, 95% CI: 0.77-0.97) and those on protease inhibitors compared to those on non-nucleoside reverse-transcriptase inhibitors (aHR after 12 months of roll-out: 0.75, 95% CI: 0.65-0.86).
Conclusion Paediatric DTG uptake was incomplete and unequitable in West African settings: DTG use was least likely in children <5years, females ≥ 10 years and those with detectable viral load. Maintained monitoring and support of treatment practices is required to better ensure universal and equal uptake.
Key messages What is already known on this topic?
Dolutegravir (DTG)-based ART regimens have been recommended as the preferred first-line ART regimens for all individuals living with HIV by the World Health Organisation since 2018, with a specific caution for pregnant women. This was subsequently confirmed for all children with approved DTG dosing and adolescents since 2019.
The deployment of universal DTG for adults in West Africa has faced challenges including infrastructure challenges, disparities in healthcare system, and initial perinatal safety concerns that significantly impacted women of childbearing age.
Specific data on DTG uptake in children, adolescents and young adults in West Africa is limited.
What does this study adds ?
This study describes the dynamic of the DTG roll-out over the first 24 months and its correlates since 2019 in a large West African multicentric cohort of children, adolescents and youth.
We observed a rapid scale-up of DTG among children, adolescents and young adults living with HIV in West Africa, despite the COVID-19 pandemic.
However, DTG uptake after 24 months was incomplete and inequitable, with adolescent girls and young women being less likely to initiate DTG compared to males, as were those with a detectable viral load (> 50 copies/mL) compared to those in success.
Younger children < 5 years were also less likely to initiate DTG, explained by the later approval of paediatric formulations and their low availability.
How may this study affect research, practice or policy?
Maintained monitoring, training and updating guidance for healthcare workers is essential to ensure universal uptake to DTG, especially for females, for whom inequity begins at age 10 years.
Efforts to improve uptake to universal DTG in West Africa require multifaceted interventions including healthcare infrastructure improvement and facilitation of paediatric antiretroviral forecasting and planning.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Research reported was supported by the National Institutes of Health (NIH) through the National Cancer Institute (NCI); Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institute of Allergy and Infectious Diseases (NIAID); Grant number: 5U01AI069919. Funders had no role in the design of the study and collection, analysis, or interpretation of the data, or the writing of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
National ethics commitees of Cote d'Ivoire, Benin, Mali, Burkina Faso, Nigeria, Togo and Ghana gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
“The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.”
The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.
Funding: Research reported in this publication was supported by the National Institutes of Health (NIH) through the National Cancer Institute (NCI); Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institute of Allergy and Infectious Diseases (NIAID); Grant number: 5U01AI069919. Funders had no role in the design of the study and collection, analysis, nor interpretation of the data, nor the writing of the manuscript.
Footnotes: Data for this study were obtained from the IeDEA pWADA coordinating team Access to the data is restricted and not publicly available. Interested researchers may contact Valériane Leroy (valeriane.leroy{at}inserm.fr) for data access requests, subject to approval and data sharing agreements.
We are updating our manuscript on medRxiv to incorporate revisions following peer review from our recent journal submission.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
